A PHASE 3 RANDOMIZED CONTROLLED STUDY OF RENAL AUTOLOGOUS CELL THERAPY (REACT) IN SUBJECTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE (REGEN-006)

Brief description of study

The main purpose of this study is to see whether REACT is safe and works to improve or stabilize kidney function when given as 2 injections approximately 3 months apart into the kidneys of people with type 2 diabetes and CKD.

Clinical Study Identifier: s25-00189

ClinicalTrials.gov Identifier: NCT05099770

Principal Investigator: Sindhuri Prakash-Polet.

Other Investigators: Michal L Melamed, David Michael Charytan, Shu Liu.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies